#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Using depot medroxyprogesteronacetate as a modern contraceptive method


Authors: Tomáš Fait
Authors place of work: 1. LF UK a VFN Praha ;  Gynekologicko-porodnická klinika
Published in the journal: Prakt Gyn 2010; 14(2): 93-95
Category: Unreviewed Post

Summary

Depot medroxyprogesterone acetate is a progestin-only long-acting reversible hormonal contraceptive agent to be injected once every 3 months. Its newer form for subcutaneous application contains 104 mg of the drug only. It is characterized by high efficacy and safety, high percentage of amenorrhea and delayed return of fertility.

Key words:
depot medroxyprogesterone acetate – contraception


Zdroje

1. Jain J, Jakimiuk AJ, Bode FR et al. Contraceptive efficacy and safety of DMPA-SC. Contraception 2004; 70(1): 11–18.

2. Čepický P, Dvořák K, Dvořák V et al. Doporučení k předpisu gestagenní kontracepce, Čes Gynek 2001, 66(2):140–142.3. Koryntová D. Gestagenní kontracepce, Mod Gyn Por 2001; 10(2): 152–159.

4. Bigrigg A, Evans M, Gbolade B et al. Depo Provera. Position paper on clinical use, effectiveness and side effects. Br J Fam Plann 2000; 26(1): 52–53.

5. Cibula D, Henzl J, Zivny J. Základy gynekologické endokrinologie. Praha: Grada 2002: 340.

6. Guiloff E. Effect of contraception on lactation. AJOG 1974; 118: 42–45.

7. Huezo C, Carignan C. Medical and service delivery guidelines for family planning. London: IPPF 1997: 298.

8. Jain J, Dutton C, Nicosia A et al. Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera. Contraception 2004; 70(1): 11–18.9. Petitti DB. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. Obstet Gynecol 2000; 95(5): 734-744.

10. Naessen T, Olsson SE, Gudmundson J. Differential effects on bone density of progestogen- only methods for contraception in premenopausal women, Contraception 1995; 52(1): 35–39.

11. Berenson AB, Rickert VI, Grady JJ. A prospective study of effects of oral and injectable contraception on bone mineral density. Obstet Gynecol 2000; 95(Suppl.4): S6.

12. Albertazzi P, Bottazzi M, Steel SA. Bone mineral density and depot medroxyprogesteron acetate, Contraception 2006; 73(6): 577–583.

13. Westhoff C. Depot medroxyprogesterone acetate contraception. Metabolic para-metrs and mood changes. J Reprod Med 1996, 41(Suppl.5): S401–S406.

14. Bigriss A, Evans N, Gbodale B et al. Depo Ptovera. Position paper on clinical use, effectiveness and side effects, Br J Fam Plann 1999, 25(2): 69–76.

15. Kunitz AM. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. J Reprod Med 1996; 41(Suppl 5): 419–427.

Štítky
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicine
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#